Finoriq

Finoriq research workspace

JOHNSON & JOHNSON (JNJ) Historical Metrics

Johnson & Johnson engages in the research and development, manufacture, and sale of a range of products. Review JNJ valuation ratios, fundamentals, and filing metrics on Finoriq.

Company Snapshot

Johnson & Johnson, together with its subsidiaries, engages in the research and development, manufacture, and sale of a range of products in the healthcare field worldwide. It operates in two segments, Innovative Medicine and MedTech. The Innovative Medicine segment offers products for various therapeutic areas, such as oncology, immunology, neuroscience, pulmonary hypertension, infectious diseases, and cardiovascular and metabolism distributed through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use. The MedTech segment provides a portfolio of products used in the surgery, orthopedic, cardiovascular, and vision fields distributed through wholesalers, hospitals and retailers, and used in the professional fields by physicians, nurses, hospitals, eye care professionals and clinics. This segment also offers products and enabling technologies that support joint reconstruction, trauma, spine, sports related injuries, and others, as well as open, laparoscopic, and robotic surgical procedures; instrumentation, energy devices, stapling systems, wound closure, biosurgery products, and digital and robotic technologies; breast aesthetics and reconstruction; contact lenses under the ACUVUE brand; intraocular lenses for cataract surgery, and other products used in cataract and refractive procedures under the TECNIS brand. The company was founded in 1886 and is based in New Brunswick, New Jersey.

Company
JOHNSON & JOHNSON (JNJ)
Ticker
JNJ
Market Cap
$600.2B
Latest Price
$249.32
Industry
Biotech & Pharma

Open insider transactions

JOHNSON & JOHNSON (JNJ) Current Valuation Metrics

Static valuation preview for JOHNSON & JOHNSON (JNJ). Market data retrieved 2026-06-12. Filing currency USD.

MetricValueSource
P/EMarket cap divided by latest TTM net income.27.5xNet Income | TTM Q1 2026
P/SMarket cap divided by latest TTM revenue.6xRevenue | TTM Q1 2026
P/Operating Cash FlowMarket cap divided by latest TTM operating cash flow.25.3xOperating Cash Flow | TTM Q1 2026
Earnings YieldLatest TTM net income divided by market cap.3.6%Net Income | TTM Q1 2026
Operating Cash Flow YieldLatest TTM operating cash flow divided by market cap.4.0%Operating Cash Flow | TTM Q1 2026

Live data loads in the app

This static page shell gives search engines reliable page context. Current tables, filings, charts, and market data continue to load from Finoriq APIs after the application starts.